Wetherby, United Kingdom

Avacta is a UK-based biopharmaceutical company developing novel cancer immunotherapeutics and high performing diagnostics, based on its two proprietary platforms: Affimer and pre|CISION.


Investment Perspective

Avacta’s two proprietary platforms, Affimer proteins and pre|CISION, are central to its plans to create novel diagnostic and therapeutic products. Recent operational and strategic developments during 2022 lay the foundations for unlocking value from its Therapeutics and Diagnostics divisions. Further data from lead asset AVA6000 should confirm the clinical utility of pre|CISION, with a wider portfolio being readied to exploit the platform’s tumour-specific activation. An M&A-led growth strategy, leveraging both internal capabilities and the Affimer platform, should create a self-sustaining Diagnostics business. News flow over the next 18-24 months provides multiple value-inflection points. Our valuation is £641m, equivalent to 228p/share.

Market information

SymbolPrimary exchanges


Diagnostics build-out continues with Coris acquisition
Lighthouse | 01 Jun 2023
Building on Therapeutic and Diagnostic foundations
Update | 10 May 2023
FY22 results point to progress across Tx and Dx
Lighthouse | 25 Apr 2023

Recent News

Second milestone in AffyXell JV
05 Jun 2023
Aquisition of Coris Bioconcept
01 Jun 2023
First patient dosed in the US in AVA6000 Phase I study
27 Apr 2023
FY22 results
25 Apr 2023